2-(2,3-dimethyl-benzyl)-benzoic acid | 148807-96-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2,3-dimethyl-benzyl)-benzoic acid
• 英文别名: 2-(2,3-Dimethyl-benzyl)-benzoesaeure；2-[(2,3-Dimethylphenyl)methyl]benzoic acid
• CAS: 148807-96-9
• 化学式: C₁₆H₁₆O₂
• 分子量: 240.302
• InChiKey: YBPPEESORLCWCU-UHFFFAOYSA-N

物化性质

• 熔点：
  177.2-177.8 °C
• 沸点：
  397.9±11.0 °C(Predicted)
• 密度：
  1.123±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2,3-dimethyl-benzyl)-benzoic acid 在 乙醚 、 溶剂黄146 、 zinc(II) chloride 作用下， 生成 3,4-Dimethyl-[9]anthrol
  参考文献：
  名称：

  meso-Alkyl Anthracenes

  摘要：

  DOI：

  10.1021/ja01863a008
• 作为产物：
  描述：

  2-(2,3-dimethyl-benzoyl)-benzoic acid 在 sodium hydroxide 、 锌 作用下， 生成 2-(2,3-dimethyl-benzyl)-benzoic acid
  参考文献：
  名称：

  meso-Alkyl Anthracenes

  摘要：

  DOI：

  10.1021/ja01863a008

文献信息

• FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE
  申请人：Bezwada Rao S.

  公开号：US20090105352A1

  公开（公告）日：2009-04-23

  This invention relates to the discovery of functionalized triclosan monomers and oligomers that, when incorporated into a substrate of, or applied as part of a coating to, medical devices and/or consumer products may extend the duration of antimicrobial properties to the medical devices and/or consumer products.

  这项发明涉及发现的功能化三氯生单体和寡聚体，当它们被纳入医疗设备的基质中，或作为涂层的一部分应用于医疗设备和/或消费品时，可以延长医疗设备和/或消费品的抗菌性能持续时间。
• CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS
  申请人：Bezwada Rao S.

  公开号：US20090076174A1

  公开（公告）日：2009-03-19

  The present invention relates to the discovery of biodegradable multi-armed oligomers wherein the end groups of these oligomers have been functionalized with biologically active molecules. The resultant multi-armed oligomers end-functionalized with biologically active molecules have a controllable degradation profile. The hydrolytic degradation of oligomers of the present invention releases the biologically active compound as such with no change in native chemical structure.

  本发明涉及可生物降解的多臂寡聚体的发现，其中这些寡聚体的末端基团已经被生物活性分子功能化。末端功能化生物活性分子的多臂寡聚体具有可控的降解特性。本发明的寡聚体的水解降解会释放出生物活性化合物，其原有的化学结构不会发生改变。
• NANOMETER-SIZED PRODRUGS OF NSAIDs
  申请人：Yu John S.

  公开号：US20110086073A1

  公开（公告）日：2011-04-14

  The present invention describes nanoprodrugs of non-steroidal anti-inflammatory drug (NSAIDs) and nanoprodrugs of α-lipoic acid-containing and NSAIDs. These nanoprodrugs have antioxidant properties and stimuli-responsiveness, which can be used to treat various disease conditions.
• Topical Composition
  申请人：Spann-Wade Monique

  公开号：US20110217248A1

  公开（公告）日：2011-09-08

  Topical compositions are disclosed that are useful for delivering a therapeutic level of an NSAID to a target within a subject having a local inflammatory disorder. A composition of the present invention comprises a Drug and a solvent system, wherein the solvent system comprises at least two solvent alcohols and wherein the solvent system is present in an amount sufficient to solubilize the Drug, the solvent system is a low alkanol system, and the composition is a single phase composition. Examplary solvent systems are those for which one of the at least two solvent alcohols is polyethylene glycol, glycerin, butylene glycol, diproylene glycol, propylene glycol, ethanol, isopropanol, or a derivative therof. Optionally the local inflammatory disorder is pseudofolliculitis barbae, dermatitis, psoriasis, wounds, or sunburn.
• OPIOID-CONTAINING ORAL PHARMACEUTICAL COMPOSITIONS AND METHODS
  申请人：Evenstad Kenneth L.

  公开号：US20110275658A1

  公开（公告）日：2011-11-10

  The present invention provides sustained-release oral pharmaceutical compositions and methods of use. The sustained-release oral pharmaceutical compositions include an opioid (including salts thereof) and a salt of a non-steroidal anti-inflammatory drug (NSAID).